Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MM17
- Development stage
- Unknown
- Lead developer
- UT Southwestern Medical Center
01
Overview
MM17: sourced facts only. name: "Using forward genetics, we discovered that the cytotoxic dibenzothiazepinone MM17 inhibits NVL." [PMID:42870030]; target: "Using forward genetics, we discovered that the cytotoxic dibenzothiazepinone MM17 inhibits NVL." [PMID:42870030]; developer: "Department of Radiation Oncology, Section in Molecular Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA." [PMID:42870030]
Beyond the preview
Go deeper on MM17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MM17.